还氧合酶-2蛋白表达与卵巢癌生物学行为的相关性

目的　研究还氧合酶 - 2 (cyclooxygenase 2 ,COX 2 )蛋白表达与卵巢浆液性肿瘤发生发展的关系。方法　应用免疫印迹 (Westernblot)法对 5 4例卵巢浆液性肿瘤组织和 10例正常卵巢组织进行COX 2蛋白检测。结果　COX 2蛋白在卵巢浆液性癌组织中表达率 (81.8% )和相对含量(2 0 .0 8± 3.5 3)明显高于良性卵巢浆液性肿瘤 (0 ,15 .0 4± 0 .12 )及正常卵巢组织 (0 ,15 .33± 0 .6 0 ;P <0 .0 5 ) ;COX 2蛋白在交界性卵巢浆液性肿瘤中表达率 (90 .0 % )和相对含量 (2 0 .6 1± 3.0 3)明显高于良性卵巢浆液性肿瘤及正常卵巢组织 (P <0 .0 5 )。卵巢浆液性癌组织与交界性卵巢浆液性肿瘤、良性卵巢浆液性肿瘤组织与正常卵巢组织比较 ,COX 2蛋白表达率和相对含量差异均无显著性 (P >0 .0 5 )。COX 2蛋白表达率和相对含量在不同的临床分期 (Ⅰ +Ⅱ与Ⅲ +Ⅳ )、组织学分级、有无腹水及有无淋巴结转移间比较 ,差异均无显著性 (P >0 .0 5 )。结论　COX 2蛋白与卵巢浆液性肿瘤发生发展密切相关。COX 2可作为卵巢浆液性癌早期诊断指标及治疗靶位点

Relation between COX-2 protein expression and biologic behavior of ovarian carcinoma

OBJECTIVE: To study the relation between cyclooxygenase-2 (COX-2) protein expression and biologic behavior of ovarian carcinoma. METHODS: The level of COX-2 protein expression was detected by Western Blot assay in 54 biopsy specimens from ovarian serous tumor patients and 10 normal ovarian samples. RESULTS: The level of COX-2 protein expression and relative quantity in ovarian serous carcinoma (81.8%, 20.08 +/- 3.53) were statistically higher than those in the benign ovarian serous tumor (0, 15.04 +/- 0.12) and in the normal ovary (0, 15.33 +/- 0.60) (P < 0.05). The level of COX-2 protein expression and relative quantity in borderline ovarian serous tumor (90.0%, 20.61 +/- 3.03) were statistically higher than those in benign ovarian serous tumor and the normal ovary (P < 0.05). The level of COX-2 protein expression and relative quantity were not significantly different from ovarian serous carcinoma and borderline ovarian serous tumor (P > 0.05); as they were between the benign ovarian serous tumor and the normal ovary (P > 0.05). The level of COX-2 protein expression and relative quantity were not significantly different among different clinical stages (I + II and III + IV), different histological grades, with or without ascites or lymphatic metastasis either. CONCLUSION: COX-2 overexpression may be significantly related to the oncogenesis and development of ovarian serous carcinoma, which may be an early diagnostic parameter and, hence, an attractive target for chemopreventive strategy in the treatment of ovarian serous carcinoma.